INSMED INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
INSMED INC (INSM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $331.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-19
- INSMED INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $331.40M, a 49.75% increase from fiscal 2024.
- INSMED INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $221.30M.
- INSMED INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$158.90M, a 200.76% decline from fiscal 2022.
- INSMED INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $157.70M, a 103.22% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $331.40M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $221.30M 10-K · filed 2026-02-19 | |
| 2023-12-31 | -$158.90M 10-K · filed 2025-02-20 | $158.90M 10-K · filed 2024-02-22 |
| 2022-12-31 | $157.70M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $77.60M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $96.30M 10-K · filed 2022-02-17 | |
| 2019-12-31 | $80.90M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $71.30M 10-K · filed 2020-02-25 | |
| 2017-12-31 | -$23.30M 10-K · filed 2019-02-22 | |
| 2016-12-31 | $68.40M 10-K · filed 2018-02-23 | |
| 2015-12-31 | $52.30M 10-K · filed 2017-02-23 | |
| 2014-12-31 | $15.80M 10-K · filed 2016-02-25 | |
| 2013-12-31 | $28.00M 10-K · filed 2014-03-06 | |
| 2012-12-31 | $10.10M 10-K · filed 2013-03-18 | |
| 2011-12-31 | $10.10M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |